Jason Brown*, Adare Pharma Solutions and Kim Huynh-Ba, Pharmalytik, LLC *Corresponding Author Nitrosamine impurities have emerged as a significant challenge in the pharmaceutical industry due to their carcinogenic potential and unexpected presence in various drug products. Regulatory authorities including the FDA, EMA, and WHO have responded with strict requirements for identification, risk assessment, and control […]
